OTCMKTS:BTHE

Boston Therapeutics Competitors

$0.02
0.00 (-2.50 %)
(As of 04/14/2021 03:14 PM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.02
MA: $0.03
$0.04
52-Week Range
$0.01
Now: $0.02
$0.07
Volume110,500 shs
Average Volume162,717 shs
Market Capitalization$2.17 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.16

Competitors

Boston Therapeutics (OTCMKTS:BTHE) Vs. ACUR, ULUR, GBIM, PARNF, PVTTF, and WCUI

Should you be buying BTHE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Boston Therapeutics, including Acura Pharmaceuticals (ACUR), ULURU (ULUR), GlobeImmune (GBIM), Parnell Pharmaceuticals (PARNF), Pivotal Therapeutics (PVTTF), and Wellness Center USA (WCUI).

Acura Pharmaceuticals (OTCMKTS:ACUR) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Acura Pharmaceuticals and Boston Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acura Pharmaceuticals0000N/A
Boston Therapeutics0000N/A

Volatility & Risk

Acura Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500.

Valuation and Earnings

This table compares Acura Pharmaceuticals and Boston Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acura Pharmaceuticals$2.66 million2.67N/AN/AN/A
Boston Therapeutics$20,000.00108.35$-3,690,000.00N/AN/A

Acura Pharmaceuticals has higher revenue and earnings than Boston Therapeutics.

Profitability

This table compares Acura Pharmaceuticals and Boston Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acura Pharmaceuticals-19.89%-1.36%-34.83%
Boston Therapeutics-24,627.27%N/A-3,480.61%

Summary

Acura Pharmaceuticals beats Boston Therapeutics on 4 of the 7 factors compared between the two stocks.

Boston Therapeutics (OTCMKTS:BTHE) and ULURU (OTCMKTS:ULUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Boston Therapeutics and ULURU, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Therapeutics0000N/A
ULURU0000N/A

Earnings and Valuation

This table compares Boston Therapeutics and ULURU's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Therapeutics$20,000.00108.35$-3,690,000.00N/AN/A
ULURUN/AN/AN/AN/AN/A

ULURU has lower revenue, but higher earnings than Boston Therapeutics.

Risk and Volatility

Boston Therapeutics has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, ULURU has a beta of -2.9, suggesting that its stock price is 390% less volatile than the S&P 500.

Profitability

This table compares Boston Therapeutics and ULURU's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Therapeutics-24,627.27%N/A-3,480.61%
ULURUN/AN/AN/A

GlobeImmune (OTCMKTS:GBIM) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares GlobeImmune and Boston Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlobeImmuneN/AN/AN/AN/AN/A
Boston Therapeutics$20,000.00108.35$-3,690,000.00N/AN/A

GlobeImmune has higher earnings, but lower revenue than Boston Therapeutics.

Risk and Volatility

GlobeImmune has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for GlobeImmune and Boston Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlobeImmune0000N/A
Boston Therapeutics0000N/A

Profitability

This table compares GlobeImmune and Boston Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlobeImmuneN/AN/AN/A
Boston Therapeutics-24,627.27%N/A-3,480.61%

Summary

GlobeImmune beats Boston Therapeutics on 3 of the 4 factors compared between the two stocks.

Parnell Pharmaceuticals (OTCMKTS:PARNF) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Profitability

This table compares Parnell Pharmaceuticals and Boston Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Parnell PharmaceuticalsN/AN/AN/A
Boston Therapeutics-24,627.27%N/A-3,480.61%

Analyst Ratings

This is a summary of recent ratings for Parnell Pharmaceuticals and Boston Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Parnell Pharmaceuticals0000N/A
Boston Therapeutics0000N/A

Risk & Volatility

Parnell Pharmaceuticals has a beta of 5, suggesting that its share price is 400% more volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500.

Earnings and Valuation

This table compares Parnell Pharmaceuticals and Boston Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parnell PharmaceuticalsN/AN/AN/AN/AN/A
Boston Therapeutics$20,000.00108.35$-3,690,000.00N/AN/A

Parnell Pharmaceuticals has higher earnings, but lower revenue than Boston Therapeutics.

Summary

Parnell Pharmaceuticals beats Boston Therapeutics on 3 of the 4 factors compared between the two stocks.

Boston Therapeutics (OTCMKTS:BTHE) and Pivotal Therapeutics (OTCMKTS:PVTTF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Earnings & Valuation

This table compares Boston Therapeutics and Pivotal Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Therapeutics$20,000.00108.35$-3,690,000.00N/AN/A
Pivotal TherapeuticsN/AN/AN/AN/AN/A

Pivotal Therapeutics has lower revenue, but higher earnings than Boston Therapeutics.

Profitability

This table compares Boston Therapeutics and Pivotal Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Therapeutics-24,627.27%N/A-3,480.61%
Pivotal TherapeuticsN/AN/AN/A

Risk and Volatility

Boston Therapeutics has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Pivotal Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Boston Therapeutics and Pivotal Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Therapeutics0000N/A
Pivotal Therapeutics0000N/A

Summary

Pivotal Therapeutics beats Boston Therapeutics on 3 of the 4 factors compared between the two stocks.

Boston Therapeutics (OTCMKTS:BTHE) and Wellness Center USA (OTCMKTS:WCUI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares Boston Therapeutics and Wellness Center USA's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Therapeutics$20,000.00108.35$-3,690,000.00N/AN/A
Wellness Center USA$30,000.00228.21$-2,390,000.00N/AN/A

Wellness Center USA has higher revenue and earnings than Boston Therapeutics.

Profitability

This table compares Boston Therapeutics and Wellness Center USA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Boston Therapeutics-24,627.27%N/A-3,480.61%
Wellness Center USAN/AN/A-1,809.19%

Volatility & Risk

Boston Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Wellness Center USA has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Boston Therapeutics and Wellness Center USA, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Boston Therapeutics0000N/A
Wellness Center USA0000N/A

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are owned by institutional investors. 15.7% of Boston Therapeutics shares are owned by company insiders. Comparatively, 14.1% of Wellness Center USA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Wellness Center USA beats Boston Therapeutics on 7 of the 8 factors compared between the two stocks.


Boston Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.32-17.9%$8.38 million$2.66 million-10.71
ULUR
ULURU
0.3$0.28-0.0%$8.17 millionN/A0.00Decrease in Short Interest
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.53-17.4%$7.25 millionN/A0.00
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36-0.0%$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08-0.0%$7.15 millionN/A0.00News Coverage
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.06-6.7%$6.39 million$30,000.000.00Gap Down
KAYS
Kaya
0.7$0.47-8.1%$6.23 million$1.01 million0.00Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72-4.2%$5.65 million$9.47 million0.00Gap Down
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23-4.8%$5.19 million$3.48 million-1.92News Coverage
Gap Up
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-16.7%$4.56 millionN/A0.00Gap Down
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11-4.3%$4.49 million$3.65 million0.00Decrease in Short Interest
AMBS
Amarantus BioScience
0.0$0.01-1.8%$4.13 millionN/A0.00Increase in Short Interest
Gap Up
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-1.3%$3.45 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
RSPI
RespireRx Pharmaceuticals
0.5$0.04-5.6%$3.00 millionN/A-0.09
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17-15.2%$2.94 millionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
NSPX
Inspyr Therapeutics
0.5$0.02-1.3%$2.34 millionN/A0.00Gap Down
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48-6.2%$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-5.6%$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09-0.0%$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-21.6%$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51-5.9%$1.69 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$2.00-5.0%$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.4%$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.25-79.4%$1.12 millionN/A-2.76Decrease in Short Interest
News Coverage
Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-19.7%$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02-10.4%$1.05 millionN/A0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21-4.8%$1.03 millionN/A0.00Decrease in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-2.1%$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03-0.4%$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-12.9%$928,000.00N/A0.00Increase in Short Interest
News Coverage
ATRX
Adhera Therapeutics
0.0$0.08-0.0%$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-125.0%$772,000.00N/A0.00Gap Up
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02-36.3%$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00-20.0%$678,000.00N/A0.00Increase in Short Interest
Gap Down
SKVI
Skinvisible
0.7$0.15-0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15-1.0%$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17-0.0%$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07-0.0%$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-17.6%$374,000.00N/A0.00Increase in Short Interest
Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03-0.0%$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09-5.9%$124,000.00N/A0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.02-0.0%$118,000.00$20,000.000.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.